Business Wire

Seoul Viosys Begins Mass Production of 25Gbps VCSELs for 5G Communication Applications

Share

Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor provider, announced that for the first time in Korea, Seoul Viosys succeeded in developing vertical cavity surface emitting laser (VCSEL) technology, a near-field-only 25Gbps laser diode compatible with 5G wired networks for transmitting and receiving, and has started mass production to supply these products to three initial customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005444/en/

[Figure 1] Schematic diagram of 5G network application using Seoul Viosys’ VCSELs (Graphic: Business Wire)

[Figure 1] Schematic diagram of 5G network application using Seoul Viosys’ VCSELs (Graphic: Business Wire)

VCSEL is a laser diode technology that converts electrical signals into optical signals. It has recently attracted attention as a light-based communication technology that achieves ultra-high-speed data communication in 5G environments. This technology is necessary for AR/VR, 3D sensing and the camera-applied ToF (Time of Flight) for smartphones, and automotive LiDAR. Seoul Viosys’ VCSELs for sensor applications have already received customers’ approval and will be mass-produced within the first quarter of 2021, and the LiDAR technology is also undergoing the approval process to be supplied to an automotive system solution provider. According to the Yole Développement, a leading compound semiconductor research firm, the global VCSEL market is expected to grow 18.4% annually from $1.1B in 2020 to $2.7B in 2025.

The 25Gbps VCSEL developed by Seoul Viosys is a high-performance laser diode technology that emits light vertically from semiconductor substrates to enable fast communication. Currently, the 25Gbps VCSEL market has seen three large U.S. companies – II-VI, Lumentum, and Broadcom – involved in a power struggle for these high value-added products, which have more than 10 times of selling price that of LED. Seoul Viosys’ VCSEL can be implemented in a single channel or four-channel configurations, depending on its intended use, and the four-channel implementation features 100Gbps (4x) of high-capacity and high-quality data reception and transmission. Although the VCSEL technology exhibits a high degree of difficulty in implementation, it is expected to cover a wide range of applications in the future, as it is price competitive compared to horizontal-type laser diodes that emit light from the sides.

“As the paradigm shift has progressed in the recent noncontact era, interest in VCSEL technology is growing, since it is a critical technology for implementing the Internet of Things (IoT) environment. Seoul Viosys will continue to research and develop the VCSEL technology to expand and apply our differentiated VCSELs to 5G communication-based smart cities, autonomous driving applications, AR/VR, and industrial IoT markets,” said an official at Seoul Viosys.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.

Contact information

Media Contacts:
Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Physicians’ Education Resource® Hosts the 38th Annual Miami Breast Cancer Conference® in Expanded, Interactive Virtual Meeting Format24.2.2021 19:12:00 CETPress release

As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/ Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami, and will bring the educational experience directly to health care professionals online. For 37 years, the historic multidisciplinary Mi

HRH Prince Mohammed bin Salman Announces Soudah Development Company (SDC)24.2.2021 19:00:00 CETPress release

His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Deputy Prime Minister and Chairman of the Public Investment Fund (PIF), has announced the launch of Soudah Development Company (SDC) in the Asir region in Saudi Arabia. The new entity, fully owned by the Public Investment Fund (PIF), will lead the development of a luxury mountain destination with immersive cultural experiences and celebration of the natural assets empowering the local and national economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005860/en/ HRH Prince Mohammed bin Salman announces Soudah Development Company (SDC) (Photo: AETOSWire) Launched to be a key driver of the Kingdom’s Vision 2030 ambitions, SDC will infuse USD 3 billioninto infrastructure and tourism projects, aimed at enhancing the visitor experience in Soudah and parts of Rijal Alma'a Governorate in the Asir region of Saudi Arabia. The planned developme

Seglan Payments Solution Provider Turns to Verimatrix for Efficient, Time-Tested Security24.2.2021 17:45:00 CETPress release

Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Seglan, an existing Verimatrix Code Protection customer and leading provider of secure payment solutions, recently selected the Verimatrix Mobile Payments technology to provide global banks and processors with time-trusted security. Seglan previously developed their own mobile payment Software Developer Kit (SDK) for implementation across its customer base. It’s now in the process of deploying Verimatrix’s mobile payments SDK that offers existing certifications for streamlining Seglan’s go-to-market capabilities aimed at some of the largest financial institutions in Europe and South America. The Verimatrix security tool will continue to be used for Seglan’s 3DSecure SDKs (certification included) while also aiming to provide their customers a full HCE and 3DSecure solution all contained within a single server. “Having successfully relied upon Ve

EnTrust Global’s Julian Proctor to Present at Economist’s World Ocean Summit24.2.2021 17:02:00 CETPress release

Julian Proctor, Portfolio Manager of EnTrust Global’s Blue Ocean 4Impact Fund (“BO 4Impact”), will join Elisabeth Munck af Rosenschöld, Head of Supply Chain and Sustainability at IKEA, Sadan Kaptanoglu, President of BIMCO, Jeremy Nixon, Chief Executive of Ocean Network Express Co., and Craig Jasienski, Group Chief Executive at Wallenius Wilhelmsen at The Economist’ World Ocean Summit panel entitled “Shipping: Collaborating across industry and supply chains to reduce emissions.” Blue Ocean 4Impact is part of EnTrust Global’s $2+ billion maritime investment platform and is launching one of the first companies that will own and lease environmentally-advanced vessels and other marine infrastructure assets to large corporate operators and end-users, in order to help reduce carbon emissions and other pollution generated by the ocean economy. The Summit is the pre-eminent global event bringing together the widest cross-section of ocean stakeholders each year, from business to government to ci

New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection24.2.2021 17:00:00 CETPress release

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology. The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes. The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the pre

Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management24.2.2021 16:22:00 CETPress release

Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses. “After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Ja

Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion24.2.2021 16:00:00 CETPress release

Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/ VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire) T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients. Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorpo